Plain-English translation of NCT06102772 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether adebrelimab—a type of immune-boosting medication—combined with two other cancer drugs (fruquintinib and paclitaxel) can help patients with advanced stomach cancer whose cancer has progressed after an initial round of chemotherapy. The study wants to see if this medication combination is effective and safe when used as a second-line treatment, especially for patients who have not yet received certain immune-boosting drugs.
Many patients with advanced stomach cancer don't benefit enough from first-line immunotherapy treatments, and some patients never receive those drugs at all. This trial exists to find out whether this medication combination could provide a better second treatment option for these patients who have limited choices after their initial treatment stops working.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive three medications as part of your treatment: fruquintinib as a pill taken for 14 days, paclitaxel (or albumin-paclitaxel) as an infusion, and adebrelimab as an infusion. These medications are given in cycles repeating every 3 weeks. You will have regular clinic visits for blood tests, imaging scans, and check-ins to monitor how the treatment is working and to watch for any side effects. The study expects to enroll about 30 patients total.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Enrollment target
~30 participants
Started
November 2023
Primary completion
October 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ting Deng, MD
Tianjin Medical University Cancer Institute and Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.